Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311-nm narrowband ultraviolet B in the treatment of psoriasis

Köllner, Katja; Wimmershoff, M. B.; Hintz, C. J.; Landthaler, Míchael; Hohenleutner, Ulrích

doi:10.1111/j.1365-2133.2005.06533.x

Cited by 82 publications

(71 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results agree with those of Kollner et al[ 11] in a recently published study. The sample size of the present study was rather small, and a significant difference of the two treatment modalities might have been observed in a larger cohort.…”

Section: Discussionsupporting

confidence: 83%

“…Considering the fact that the excimer laser selectively targets affected skin areas and that psoriatic lesions can tolerate much higher doses of UV light than adjacent healthy skin, we can assume that it is possible to observe faster and maybe even better clinical results using this newer monochromatic light delivery instead of narrow-band UVB phototherapy in the treatment of psoriasis. However, there are very few data comparing the clinical effects of narrow-band UVB and excimer laser treatment in psoriasis [11]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Excimer Laser versus Narrow-Band UVB (311 nm) in the Treatment of Psoriasis Vulgaris

Goldinger

Dummer

Schmid³

et al. 2006

Dermatology

View full text Add to dashboard Cite

Background: The excimer laser is a new therapeutic option in the treatment of psoriasis vulgaris. Objective: The purpose of this study was to determine the response of psoriasis lesions to the 308-nm excimer laser compared to 311-nm UVB phototherapy. Methods: In this prospective right/left comparative, open, single-blinded trial, selected psoriasis plaques of 16 patients were treated with the excimer laser whereas the rest of the body was treated with UVB narrow-band phototherapy. A modified PASI score was used to evaluate the results. Results: After 12 treatments, 15 patients were evaluated. In 2 patients no difference between the two body sides was observed. In 9 patients the laser-treated lesions showed better results, whereas in 4 patients the side treated with 311-nm UVB showed more clearing. The mean reduction in PASI score was 5.6 and 4.9, respectively (difference not significant). Conclusion: The use of the 308-nm xenon chloride excimer laser is an additional effective therapeutic option for the treatment of psoriasis vulgaris.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Excimer Laser versus Narrow-Band UVB (311 nm) in the Treatment of Psoriasis Vulgaris

Goldinger

Dummer

Schmid³

et al. 2006

Dermatology

View full text Add to dashboard Cite

show abstract

“…These devices deliver high doses of UV radiation only to the psoriatic plaques and their use is accompanied by similar clinical response as conventional full-body phototherapy. 6,8,18,19 The use of high doses (several MEDs) is accompanied by a high incidence of short-term side-effects such as blister formation. Two independent studies reported that during treatment with the 308 nm excimer UVB laser, approximately 40% of patients developed blisters, some needing 7-14 days until complete healing.…”

Section: Discussionmentioning

confidence: 99%

“…6 This type of therapy regimens with targeted phototherapy are similar to those following conventional phototherapy. 8 The therapeutic effect of UVB radiation is mostly attributed to its immunosuppressive and immunomodulatory action. 9 The most important mechanism that explains the immunosuppressive effect of UV radiation is apoptosis induction.…”

Section: -5mentioning

confidence: 99%

Targeted phototherapy of plaque-type psoriasis using ultraviolet B-light-emitting diodes

Kemény

Csoma

Bagdi³

et al. 2010

British Journal of Dermatology

View full text Add to dashboard Cite

Summary Background One of the major technological breakthroughs in the last decade is represented by the diversified medical applications of light‐emitting diodes (LEDs). LEDs emitting in the ultraviolet (UV) B spectrum might serve as a more convenient alternative for targeted delivery of phototherapy in inflammatory skin diseases such as psoriasis. Objectives We investigated the efficacy and safety of a new UVB‐LED phototherapeutic device in chronic plaque‐type psoriasis. Methods Twenty patients with stable plaque‐type psoriasis were enrolled into a prospective, right‐left comparative, open study. Symmetrical lesions located on extremities or trunk were chosen; one lesion was treated with the study device, whereas the other lesion served as an untreated control. Two treatment regimens were used in the study, one with an aggressive dose escalation similar to those used for outpatient treatment and one with slow increase in dose, similar to those used for treatment at home. Results Patients in both groups responded rapidly to the UVB‐LED therapy. Early disease resolution was observed in 11 patients (seven in the first group and four in the second group). Overall improvement at end of therapy was 93% in the high‐dose group and 84% in the low‐dose group. Four patients from the high‐dose group and five from the low‐dose group were still in remission at the 6‐month follow‐up visit. Conclusions These results suggest that this innovative UVB‐LED device is effective in the treatment of localized psoriasis and may be useful in other UV‐responsive skin diseases.

show abstract

“…Die Wirksamkeit dieser sog. gezielten ("targeted") UVB-Therapie mittels 308-nm-Excimer-Laser konnte für die Psoriasis hinlänglich in vielen Studien in den letzten Jahren nachgewiesen werden [10,16,30]. In der Mehrzahl der Studien kann bei ungefähr 80% dieser Patienten nach bis zu 12 Bestrahlungen eine vollständige Remission (Reduktion des PASI um ≥90%) erzielt werden [10,29,37].…”

unclassified

Targeted UVB-308 nm (NUVB) therapy with excimer laser in the treatment of atopic dermatitis and other inflammatory dermatoses

2009

View full text Add to dashboard Cite

UVB 311 nm phototherapy (NUVB) is used successfully in the treatment of psoriasis or atopic dermatitis and is often chosen as "first-line" therapy. In a prospective study we investigated the efficacy of the targeted UVB 308 phototherapy by excimer laser in the treatment of 57 patients with localized, mild therapy-resistant atopic dermatitis. We achieved a complete remission (CR) in nearly 85% and a partial remission (PR) in 15% after 10 treatments during 6-8 weeks in all patients. A mean reduction in patient-reported pruritus was one hallmark after 3-4 treatments. 48 other patients with lichen simplex chronicus Vidal, nodular prurigo, granuloma anulare, alopezia areata (AA) and lichen ruber planus were also treated by targeted NUVB. We found higher rates of CR and PR only in patients with AA and in patients with oral Lichen ruber mucosae. These results and the systematically reviewing of the current medical literature shows that targeted NUVB by excimer laser cannot be successfully transferred for all inflammatory skin diseases. In particular, Excimer UVB treatment expands the therapeutic options in patients with localized and therapy-resistant atopic dermatitis enormously.

show abstract

Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311-nm narrowband ultraviolet B in the treatment of psoriasis

Abstract: Both 308-nm light sources can clear patch psoriasis in a similar manner to standard phototherapy, with the advantage of the ability to treat exclusively the affected skin and with a reduced cumulative dose, thus perhaps reducing the long-term risk of carcinogenicity.

Cited by 82 publications

References 14 publications

Excimer Laser versus Narrow-Band UVB (311 nm) in the Treatment of Psoriasis Vulgaris

Excimer Laser versus Narrow-Band UVB (311 nm) in the Treatment of Psoriasis Vulgaris

Targeted phototherapy of plaque-type psoriasis using ultraviolet B-light-emitting diodes

Targeted UVB-308 nm (NUVB) therapy with excimer laser in the treatment of atopic dermatitis and other inflammatory dermatoses

Contact Info

Product

Resources

About